xcessive inflammation is widely appreciated to be a unifying component in many chronic diseases, including vascular diseases, metabolic syndrome and neurological diseases, and thus is a public health concern. Understanding endogenous control points within the inflammatory response could provide us with new perspectives on disease pathogenesis and treatment approaches. Barrier break, trauma and microbial invasion create a need for the host to neutralize invaders, clear the site, and remodel and regenerate tissue. The acute inflammatory response is protective, providing a terrain in which lipid mediators -such as eicosanoids (prostaglandins and leukotrienes) 1,2 produced from the essential fatty acid arachidonic acid, as well as many cytokines and chemokines 3-5 -have crucial roles in the initial response. Interactions among prostaglandins, leukotrienes and pro-inflammatory cytokines amplify inflammation, the signs of which can be reduced by pharmacological inhibition and receptor antagonists [1] [2] [3] . However, given that excessive inflammation contributes to many widely occurring diseases, improvements are needed in treatment and in our understanding of the mechanisms involved.
xcessive inflammation is widely appreciated to be a unifying component in many chronic diseases, including vascular diseases, metabolic syndrome and neurological diseases, and thus is a public health concern. Understanding endogenous control points within the inflammatory response could provide us with new perspectives on disease pathogenesis and treatment approaches. Barrier break, trauma and microbial invasion create a need for the host to neutralize invaders, clear the site, and remodel and regenerate tissue. The acute inflammatory response is protective, providing a terrain in which lipid mediators -such as eicosanoids (prostaglandins and leukotrienes) 1, 2 produced from the essential fatty acid arachidonic acid, as well as many cytokines and chemokines [3] [4] [5] have crucial roles in the initial response. Interactions among prostaglandins, leukotrienes and pro-inflammatory cytokines amplify inflammation, the signs of which can be reduced by pharmacological inhibition and receptor antagonists [1] [2] [3] . However, given that excessive inflammation contributes to many widely occurring diseases, improvements are needed in treatment and in our understanding of the mechanisms involved.
Pathologists divide the acute inflammatory response into initiation and resolution (Fig. 1) . Resolution was considered to be a passive process 6 . With the identification of mediators with proresolving capacity that could be biosynthesized from omega-3 (or n-3) essential fatty acids (EFA), evidence emerged that resolution of self-limited acute inflammation might be an active, programmed response that is 'turned on' in animal models, and not simply a process of passive dilution of chemoattractants 7, 8 . For a metabolite to fulfil the role of mediator, it must be produced in sufficient amounts in vivo to evoke bioactions. The omega-3 fatty acids EPA and DHA, which are found in marine oils, have long been thought to have anti-inflammatory properties, whereby they compete with arachidonic acid, reducing pro-inflammatory eicosanoids 9 . The molecular mechanism by which this occurs is unclear, and the evidence is inconclusive as to whether omega-3 EPA and DHA are beneficial for human health and as treatments for disease. Resolving inflammatory exudates use omega-3 fatty acids ( Fig. 1 ) to produce structurally distinct families of signalling molecules -resolvins, protectins and maresins, collectively termed specialized pro-resolving mediators (SPMs). This realization prompted new interest in resolution pathways and the innate immune mechanisms for homeostasis. SPMs are agonists with the potential to stimulate key cellular resolution events, namely limiting polymorphonuclear neutrophil infiltration and enhancing macrophage clearance of apoptotic cells 5, 6 , as shown in pre-clinical studies using animal models 10 . This Review addresses the role of novel lipid-derived SPMs in resolution that also function in host defence, pain and tissue regeneration, which could help us to understand the role of SPM pathways in human resolution physiology.
Cellular events in resolution of acute inflammation
During the initiation phase, leukocytes traffic from circulation to the site of trauma or microbial invasion, forming inflammatory exudates -conventionally these are considered to be the 'battlefields' where most resolution occurs 6 . The first responders, neutrophils, swarm like bees to defend the body, moving along chemotaxic gradients (for example, increasing levels of the leukotriene LTB 4 ) 11 , and exiting venules governed by prostaglandins (such as PGE 2 and PGI 2 ) that act on vascular cells and blood flow 1 (Fig. 1 ). These lipid mediators, along with many cytokines, chemokines and complement components (C5a and C3b), stimulate the chemotaxis of neutrophils into tissues to phagocytize and neutralize invaders [3] [4] [5] [6] . Many therapeutic agents block or antagonize the initiation steps of acute inflammation (for example, prostaglandin biosynthesis inhibitors or chemokine receptor antagonists) 1, 3, 12 . At a cellular level, the main events of resolution are the cessation of neutrophil influx and efferocytosis (macrophage clearance of debris, including apoptotic neutrophils) 4, 5 . The protective acute inflammatory response evolved to permit the repair of injured tissues and eliminate invading organisms. Ideally, it is a self-limited process, leading to complete resolution that enables a return to homeostasis (Fig. 1) . By studying self-limited inflammation in animal models, and using a systems approach to investigate resolving exudates, novel bioactive products derived from essential fatty acids were uncovered. The bioactions of these products include limited neutrophil influx in vivo, reduced human neutrophil transmigration and counter-regulation of cytokines such as tumour necrosis factor-α (TNF-α) in mice. Each bioactive product was systematically evaluated, and found to be biosynthesized from EPA and DHA by separate pathways in human neutrophils and macrophages in vitro 7, 8, 13 .
Elucidation of pro-resolving lipid-derived mediators
The anti-inflammatory process is not equivalent to pro-resolution, which involves SPMs acting as agonists to stop further neutrophil influx and the activation of nonphlogistic responses by macrophages and resolution programs (Fig. 1) . The key to understanding this difference was the identification of novel families of autacoids and forms of these molecules that could potentially be triggered by aspirin, providing evidence that, in animal models, resolution is actively orchestrated by lipid mediators ( Fig. 2 and Box 1). Harnessing the pathways that stimulate resolution will be a challenge for the future 14 . Omega-3 fatty acids are a widely taken dietary supplement, but less than 25% of these supplements are prescribed by health-care providers 15 . Given the mixed results 16 on the benefit of these supplements in clinical trials, it is crucial for public health that the mechanisms that underlie their requirement are established.
Using a systems approach with resolving mouse exudates was key to elucidating SPM actions and pathways 4, 8 . Biosynthesis with human leukocytes and complete stereochemistry of each major resolvin (RvE1, RvD1, RvD2, RvD3 and RvD5), protectin and maresin was accomplished by matching these mediators with those prepared by total organic synthesis, which also confirmed their potent bioactivity 10, 17 . Resolvins and protectins control the magnitude and duration of inflammation in animal disease models 18 , and can, for example, increase animal survival 10 (Fig. 2) . The potent in vivo actions of RvD1 and RvD2 are reported in many pathologies, such as obesity and pathologies affecting the vascular 19 , airway 20 , dermal, renal and ocular systems, and in processes including pain, fibrosis and wound healing 10, 21 . Their role in governing neutrophil influx, resolution macrophages and reducing pro-inflammatory mediators (PAF, LTB 4 and prostaglandins) seem to be fundamental in all organs.
Resolvin D3 and the maresin pathway
Within self-limited exudates, RvD3 has a unique time frame compared with RvD1 and RvD2. In mouse peritonitis, RvD3 appears late in resolution, suggesting it has a specific role. The complete stereochemistry of RvD3 was recently established 22 , confirming its potent anti-inflammatory and pro-resolving actions 8 . Macrophage biosynthesis of maresin MaR1 and its potent pro-resolving and tissue regenerative actions 23 ( Fig. 2) involve an active 13S,14S-epoxidemaresin intermediate, stimulating a macrophage phenotype switch from M1 to M2 (ref. 24) (Fig. 2) . The switch towards the M2 phenotype is associated with reparative and anti-inflammatory macrophage functions 5, 25 .
Resolution agonists and resolution disrupters
Several lessons have emerged from recent studies. Prostaglandins are central to vascular responses, permitting neutrophils and monocytes to leave post-capillary venules (a process called diapedesis). Their production through COX-1 and COX-2 (also known as prostaglandin G/H synthase 1 and 2) is crucial for initiation and timely resolution 26, 27 (Fig. 2) . After barrier break, tissue injury or trauma, eicosanoids are crucial in initiating the cardinal signs of inflammation (redness, heat, pain and swelling). As part of the vascular response, leukocytes traffic to the site of injury. The prostaglandins PGE 2 and PGI 2 (involved in vasodilation) and the leukotriene LTB 4 (involved in chemotaxis and adhesion) stimulate the migration of neutrophils to the tissue. As part of the neutrophil-monocyte sequence, lipid mediator (LM) class switching from eicosanoids to lipoxins signals 'stop' and begins the end of the acute inflammatory response. Lipoxins and resolvins stimulate the recruitment of non-phlogistic monocytes. The resolving macrophages then clear apoptotic neutrophils in a process called efferocytosis (stimulated by resolvins and protectins). After this has taken place normal structure and homeostasis can be restored. Signs of resolution include sequestration of pro-inflammatory cytokines, clearance of neutrophils from epithelial surfaces, phagocytosis of apoptotic neutrophils and removal of inflammatory debris and microbial invaders. Failed resolution can lead to increased levels of prostaglandins and leukotrienes, chronic inflammation (which can be inhibited by resolvins) and fibrosis. SPMs counter-regulate pro-inflammatory chemical mediators, reducing the magnitude and duration of inflammation, and stimulate re-epithelialization, wound healing and tissue regeneration in model organisms. In addition to the release of omega-3 substrates from phospholipid stores 95 , these substrates can enter exudate as a result of oedema from peripheral blood, as shown in mice 57 . SPMs enhance efferocytosis, stimulate signs of resolution and signal to adaptive immunity. 
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of prostaglandins and LTB 4 to one with high levels of lipoxins, a process known as lipid-mediator class switching, in mouse exudates ( Fig. 1 and Box 1). PGE 2 or PGD 2 added to isolated human neutrophils increases 15-lipoxygenase type I translation from messenger RNA stores in a cyclic-AMP-dependent manner, increasing lipoxin biosynthesis (identified using MS-MS spectra) 26 . Inhibition of COX-2 delays resolution because prostaglandins have crucial roles in resolution and because they are initiators of lipid-mediator class switching (Fig. 1) , as shown in animal disease models in vivo 18, 26, 29 . When mapping resolution, it became apparent that initiation signals the end of inflammation 4 and that leukocyte traffic in pus permits prostanoids to signal the biosynthesis of other resolution mediators ( Fig. 1 and Fig. 2 ). For example, disruption of physiological lipid-mediator class switching has deleterious consequences in mouse models of arthritis 29 . To pinpoint the crucial steps and mechanisms of SPM action within inflammation resolution, it was important to introduce quantitative indices 18, 30 that enabled the assessment of resolution in vivo 21, 27, 31 . Resolution indices identified agents that stimulate as well as those that disrupt or delay resolution (resolution interval); for example, COX-2 and lipoxygenase inhibitors 18, 27, 32 . Specific SPMs shorten the resolution interval by limiting neutrophil recruitment and stimulating both macrophage efferocytosis ( Fig. 1 ) and bacterial killing 31, 33, 34 , demonstrating the neutrophil-monocyte sequence and the macrophage responses needed for tissue regeneration 23 .
Glucocorticoids, specific cyclin-dependent kinase inhibitors, statins, annexin peptides and aspirin all enable resolution 31, 35, 36 . In the same way there are many mediators in the initiation of inflammation, there are also many endogenous mediators and drugs that have an impact on resolution 5, 18, 20 . Although both aspirin and non-steroidal anti-inflammatory drugs (NSAIDs) inhibit prostanoid biosynthesis, aspirin is an irreversible inhibitor that acetylates COX-1 and COX-2, whereas other NSAIDs are reversible inhibitors 1, 2 . Aspirin acetylation of COX-2 modifies the catalytic domain, blocking prostaglandin biosynthesis 1,2 , but it remains active, producing 15R-HETE from arachidonic acid, 18R-HEPE from EPA and 17R-HDHA from DHA in cells carrying COX-2. These products can be transformed by human neutrophils in vitro to aspirin-triggered lipoxins, aspirin-triggered resolvins 7, 8 and aspirin-triggered protectins 37 . Each has a potent effect, stopping human neutrophil migration and enhancing macrophage clean up, improving resolution in mice. Whether aspirin or statins enhance the production of aspirin-triggered SPMs in humans remains to be established using mass spectral-based identification. And whether aspirin favours resolution in humans, in whom distinct resolutionphenotypes have emerged, is of considerable interest 27, 38 . In mice, intravascular LXA 4 is produced by platelet-neutrophil aggregates during ischaemia, which reduces vascular inflammation. Aspirin triggers 15-epi-LXA 4 , which was identified using LC-MS-MS, and this was less effective in mice deficient for the lipoxin receptor ALX, 
providing in vivo evidence that aspirin can jump-start resolution circuits in mice 39 .
New mechanisms in local SPM biosynthesis
Microparticles are membrane-derived vesicles produced by a range of cell types that contribute to human pathologies. Microparticles from self-resolving exudates show anti-inflammatory and pro-resolving capacity 40 in mice. Resolution microparticles enhance efferocytosis 13, 40 and carry pro-resolving signals, including hydroxy-SPMintermediates esterified in phospholipids 40 . Secreted PLA 2 (sPLA 2 ) prompts the release of pro-resolving signals from microparticles for trans-cellular conversion by human macrophages in vitro 13, 40 . Because nanomedicines are useful for local targeting and delivery, resolution microparticles, and their ability to shorten the resolution interval in mouse peritonitis, were used as a basis for biomimicry to construct humanized nanoparticles containing an LXA 4 analogue, or aspirin-triggered-RvD1 (ref. 40) . These nano-pro-resolving medicines (NPRMs), carrying SPMs or SPM analogues, enhance wound healing of human keratinocytes and are protective in a mouse model of temporomandibular joint disease characterized by inflammationinduced bone loss 40 ( Fig. 1 and Box 2). Microparticles can also transfer substrate and intermediates to macrophages during efferocytosis to enhance SPM biosynthesis, which was demonstrated by transfer of deuterium labels from precursors to SPMs (identified using LC-MS-MS) 13 . Myeloid cells at different stages have agonist-and phenotype-specific lipid mediator profiles. For example, human neutrophils from healthy peripheral blood predominantly produce LTB 4 , whereas apoptotic neutrophils produce PGE 2 , LXB 4 and RvE2 signals 13 . Both M1 and M2 macrophages have specific markers and pathways that are specialized to the functions of that subpopulation in inflammation and resolution 25 . Human M2 macrophages have more of the enzymes 41 needed for cell-type-specific lipid mediators. M2 cells produce SPM profiles with lower levels of LTB 4 and prostaglandins than M1 cells. Both cell types engulf apoptotic neutrophils, changing their lipid mediator signature profiles. In M2 cells, LTB 4 is downregulated and SPMs are increased 13 , suggesting that M1 and M2 subpopulations 25, 41 produce functional lipid mediator signatures that can affect both physiological and pathophysiological states 13 . In addition, group IID sPLA 2 was identified as a resolving sPLA 2 that was expressed in dendritic cells and macrophages that release substrates with the capacity for producing RvD1 and PGJ 2 , as identified by mass spectrometry in mouse lymphoid tissue in vivo 42 . The functional contributions of this resolving sPLA 2 to the inflammatory response in humans is unknown.
The role of eosinophils is well appreciated in parasitic infections and allergic responses. In patients with severe asthma, protectin D1 (PD1) is present in exhaled breath condensates 43 , and is lower in eosinophils from these patients 44 . Human eosinophils produce PD1, which reduces adhesion molecules (CD11b and L-selectin), eotaxin-1 and chemotaxis at nanomolar concentrations, without affecting degranulation, superoxide generation or cell survival. Eosinophils also stimulate resolution in mouse peritonitis through SPMs initiated by mouse eosinophils 45 . LC-MS-MS-lipidomics identified LXA 4 , RvD5, 17-HDHA and PD1 from eosinophils, and RvE3 in vivo (Fig. 2) , which limit neutrophil infiltration and regulate macrophages [44] [45] [46] . Hence, by their ability to produce SPMs, eosinophils might contribute to resolution. In support of this, eosinophil depletion has been found to lead to failed resolution, which is rescued by PD1 or eosinophil restoration in mice. Thus, cellular traffic to sites of inflammation has a dynamic impact on lipid mediator signatures and specific SPM metabolomes activated within the local milieu.
SPM cellular actions in disease models
SPMs increase survival in diverse mouse models; for example, inflammation and tissue injury in the airway, skin and eye that result from collateral damage are improved with exogenous SPMs 10 . The SPM nanomolar doses required to stop ongoing inflammation and promote resolution rely on G-protein-coupled receptors (GPCRs). Several SPM receptors have been identified using GPCR screening, labelled ligands for specific binding (stereospecific nanomolar dissociation constant) and functional cellular responses [47] [48] [49] . In general, SPMs do not utilize intracellular calcium (Ca 2+ ) mobilization in neutrophils for signal transduction but instead activate phosphorylation. RvE1 specifically binds to the receptors ChemR23 (ref. 47 ) and BLT1 to evoke pro-resolving responses. RvE1 activation of ChemR23 enhances macrophage phagocytosis by phosphoprotein-mediated signalling 48 . RvE1 blocks LTB 4 binding and promotes, through BLT1, apoptosis of neutrophils for their clearance by macrophages 49 , whereas LTB 4 -BLT1 signals neutrophil survival. The blocking of survival signals to neutrophils by RvE1 marks an important difference from the process that occurs in the innate response, in which neutrophils must undergo timely apoptosis for clearance 5, 49 (Fig. 2) . RvD1 binds and activates the human receptor GPR32, and binds to both the human and murine forms of the LXA 4 receptor (called ALX/ FPR2). Transgenic mice overexpressing human ALX/FPR2 require Bioactive products of omega-3 were originally isolated from mouse resolving exudates. The structure of these products was elucidated, and the biosynthesis of each new omega-3 family from EPA and DHA was recapitulated with isolated human neutrophils 8, 20 and macrophages in vitro 23, 24 . Biosynthesis of E-series resolvins is initiated by the molecular oxygen insertion at the carbon-18 position of EPA produced by hypoxic human endothelial cells and acetylated COX-2, or p450. Microbial p450 (ref. 7) (Fig. 2, left) also produces 18-HEPE, which is converted to bioactive E-series members by human neutrophils. Both aspirin-dependent and independent formation occurs in human peripheral blood 47, 61 . The resolution metabolome also activates 17-lipoxygenation of DHA by hydrogen abstraction; 17S-HpDHA is converted to resolvin-epoxide-containing intermediates (Fig. 2, centre) that are transformed to resolvins D1-D4 by human neutrophils, each identified using methods such as mass spectrometry of bioactive products. The 17S-HpDHA intermediate is also a precursor to 16,17-epoxide-protectin, which is converted to protectin D1/neuroprotectin D1 and related structures by human leukocytes (neutrophils and T cells), neural cells and retinalpigmented epithelial cells 8, 97, 98, 112 . Maresins isolated from human and mouse macrophages are produced by initial lipoxygenation with molecular oxygen insertion at the carbon-14 position to form the hydroperoxide intermediate, which is rapidly converted to 13S,14S-epoxide-maresin and enzymatically converted to maresin-1 (ref. 24) (Fig. 2, right) . Lipoxygenase mechanisms involve hydrogen abstraction and molecular oxygen insertion at specific carbon positions that are predominantly in the S configuration. Aspirin, by COX-2 acetylation and p450 enzymes, contributes to the biosynthesis of R-configuration alcohols in lipoxins, resolvins and protectins 37 . The stereochemistry of each bioactive specialized pro-resolving mediator family member (Fig. 2) has been determined, and the biosynthesis and potent pro-resolving and anti-inflammatory actions in murine exudates and human tissues has been confirmed (see ref. 17 for original reports and refs 10, 20 for reviews). 
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less RvD1 than wild-type mice to stop inflammation 50 , and in receptordeficient mice, RvD1 seems to have no leukocyte-directed actions 51 . Resolution involves specific microRNAs (miRNAs) regulated by SPM receptors 50, 52, 53 . RvD1-GPR32 upregulates miR-208 and anti-inflammatory interleukin-10 (IL-10), and downregulates miR-219, decreasing LTB 4 levels through the regulation of 5-lipoxygenase 52 . This miRNA regulation is an example of SPM signalling with a sustained tissue impact.
SPM receptors are also rapid signallers. For example, recombinant RvD1-GPR32 blocks histamine H1 receptor-stimulated increases in intracellular Ca 2+ in Chinese hamster ovary (CHO) cells by rapidly stimulating the phosphorylation of the H1 receptor, stopping Ca 2+ mobilization 54 . This form of SPM signalling, which has been reported in conjunctival goblet cells and RvD1, is also functional in salivary glands 55 and is probably relevant in human neutrophils, which rapidly stop chemotaxis in microfluidic chambers and change shape on exposure to SPMs 56, 57 . RvD3 and RvD5 can also activate recombinant GPR32 (refs 22, 33) . Given the temporal production of RvD3 in vivo 22 ( Fig. 2) , these findings underscore that locally produced SPMs can affect different cell types and receptors with a spatio-temporal dependency. In addition to RvD1 and LXA 4 , ALX/FPR2 is activated by peptide pro-resolving mediators, such as annexin A1, as well as high concentrations of pro-inflammatory peptides 36 . This capacity of ALX/FPR2 involves ligand-biased receptor activation and heterodimerization of ALX/FPR2, with related FPRs dictating pro-inflammatory signalling and homodimerization of ALX/FPR2 determining pro-resolving signalling 36 . LXA 4 also enhances the activity of the ALX/FPR2 promoter, which is mutated in human cardiovascular disease 58 .
Infection and resolution programs
Topical RvE1 and LXA 4 each reduce the severity of periodontal disease in rabbits by enhancing clearance of the causative organism Porphyromonas gingivalis 59, 60 . Although the anti-inflammatory actions of SPMs were uncovered in sterile inflammation models 7, 8 , the relationship between resolution and infection is of interest because of the known eventual A number of steps have led to the possibility of assessing SPM function in humans (Box 2 Fig.) . The molecules derived from omega-3 and their bioactions have been identified in the resolving inflammatory exudates of mice. Studies have reported the structure of these molecules, their actions with human neutrophils and their proposed biosynthesis from EPA and DHA using 18-oxygen, 14-carbon and trapping of transient intermediates 17 . Confirmation of the bioactive structures and total organic synthesis to assign complete stereochemistry to each specialized pro-resolving mediator (SPM) family member required the development of a strategy to match the biologically active isolated product with those prepared by total organic synthesis. NMR (nuclear magnetic resonance) confirmed the geometry of the conjugated double bond systems present in SPMs; for example, RvE1 (ref. 47 SPMs have been identified as conserved structures that are present in trout (PD1 and RvD1) 88 , salmon (RvD1 and RvD2) 117 and planaria (RvE1 and MaR1) 23 . Microfluidic chambers that permit visualization of cell-cell interactions between leukocyte subpopulations (human neutrophils and monocytes) and distinguish phlogistic compared with non-phlogistic phagocyte behaviour are ideal for screening SPMs and humanized nano-pro-resolving medicines (NPRMs) 40, 56 . This single-cell screening permits the optimization of enrichment of microparticles with SPMs, the production of NPRMs and the viewing of neutrophilmonocyte interactions 56, 57 , which are essential for appreciating the signals that occur during the neutrophil-monocyte sequence (Fig. 1) .
Using microfluidic chambers, single human neutrophils were assayed within about 5 minutes of their capture from whole blood (minimizing the isolation time reduces potential artefacts). Nanomolar concentrations of each SPM prevents human neutrophil migration to interleukin-8 (IL-8), whereas at equimolar doses the precursor (DHA) is not active 56, 57 . Resolution indices permit the quantitative assessment of SPM actions in animal models 18, 30 ; this is essential for defining the SPMs within the integrated response of the host to acute inflammatory challenges. Demonstration and identification of omega-3 SPMs in human tissues is required so that we can appreciate their potential roles in humans. RvE1 and RvE2 (refs 47, 61) were identified in the peripheral blood of healthy volunteers, some of whom had been given EPA supplements, using LC-MS-MS multi-reaction monitoring. RvD1, RvD2 (ref. 111 ), PD1 and 17-HDHA were identified in the exhaled breath condensates of people with asthma 43 ; and additional SPMs were identified in human adipose tissue 118 , the brains of people with Alzheimer's disease 96, 101 , and patients with multiple sclerosis 119 and rheumatoid arthritis 120 using mass spectral identification. Although, at present, the demonstration of omega-3 in human tissues is in the initial stages, with the capabilities of LC-MS-MS-based profiling 13 , SPMs could have potential as markers for nutritional status. The field is now set with tools for assessing SPM function in humans and the relationships of SPMs with nutrition and disease.
BOX 2
Omega-3 pro-resolving mediator structure, function and steps towards human translation 
REVIEW INSIGHT
immunosuppressive actions of anti-inflammatory drugs 12 . Surprisingly, RvD2 protects mice from caecal ligation puncture (CLP)-induced sepsis 34 ; it has potent actions, enhancing phagocytosis and bacterial killing. In self-limited Escherichia coli infections, resolution programs are activated in mice, and levels of host PD1, RvD5 and RvD1 are elevated 33 . When SPMs identified in vivo were added back to mouse phagocytes, human macrophages or neutrophils as synthetic SPMs, they enhanced bacterial phagocytosis and killing, as well as clearance 33, 34, 61 . Importantly, when the host is given SPMs that are known to act on the host, lower antibiotic doses are needed to clear infections 33 . Exogenous LXA 4 is also protective in rat CLP-induced sepsis, reducing bacterial burden and pro-inflammatory mediators through a macrophage nuclear-factor-κB (NF-κB)-mediated mechanism, which reduces systemic inflammation 62 . Aspirin-triggered-LXA 4 increases E. coli phagocytosis in a phosphatidylinositol-3-OH kinase (PI(3)K)-and scavenger receptor-dependent manner, and ALX/FPR2 is upregulated in patients with Crohn's disease and enhances bacterial clearance 63 . Mycobacterium tuberculosis infections are susceptible to modulation of LTA 4 hydrolase. Besides altering LTB 4 , this may also engage resolution programs by activating LTB 4 -LXA 4 production, regulating host responses in zebrafish, mice and possibly in humans 64, 65 . Given the problem of rising antibiotic resistance, activation of resolution programs could provide new antimicrobial approaches to lower our exposure to antibiotics 33 . The herpes simplex virus causes ocular infections that lead to stromal keratitis with viral-initiated immunopathology. RvE1 and PD1 are both potent and topically active in mouse models of the infection, reducing pro-inflammatory mediators and stimulating 67) . Lethal dissemination of the H5N1 virus activated genes in mice that are associated with lipoxin biosynthesis, whereby sustained inflammation inhibited lipoxin-mediated anti-inflammatory host responses, permitting viral dissemination 68 . H5N1 activates the host resolution-metabolome increasing PD1 levels (identified by LC-MS-MS) 69 . Host protectins show antiviral activity, blocking replication of the H5N1 influenza virus. During the time course of infection with the low-pathogenicity strain of influenza H3N2, anti-inflammatory mediators are produced that correlate with resolution and SPM-related pathway markers 70 . SPMs are also found in yeast infections; for example, Candida albicans infections, in which RvE1 enhances yeast killing and clearance in mice 71 . These results support the idea that treating the infected host with host-directed pro-resolving molecules could provide new opportunities to reduce inflammation and enhance clearance by exploiting host-pathogen interactions 33, 61, 72 .
Chronic inflammatory disease models
Periodontal disease is a chronic inflammatory disease in which infection leads to neutrophil-mediated tissue injury around the tooth. Activated neutrophils from patients with periodontitis produce PGE 2 , LTB 4 and LXA 4 , each identified using LC-MS-MS 73 . PGE 2 in this tissue leads to bone loss. P. gingivalis elicits neutrophil recruitment in mouse air pouches along with COX-2 upregulation. LXA 4 stable analogues reduced both neutrophil influx and COX-2 expression that was associated with the oral pathogen 73 . In addition, P. gingivalis increased COX-2 expression in the lung and heart of mice, and 16S ribosomal RNA of P. gingivalis was present in these tissues, providing evidence of a role for this oral pathogen in the development of systemic inflammation. Transgenic rabbits overexpressing human 15-lipoxygenase type I produce 6-10 times the amounts of LXA 4 , which was identified using LC-MS-MS, than wildtype-rabbits 59 ; transgenic rabbits have less bone loss in periodontitis and markedly reduced neutrophil recruitment and vascular leakage through their skin on immune challenge compared with wild-type rabbits, suggesting that overexpression of lipoxin biosynthesis is protective and could be useful in controlling inflammation-mediated bone destruction 59 . Unexpectedly, overexpression of 15-lipoxygenase in these transgenic rabbits sharply reduces atherosclerotic lesions 74 . In 12/15-lipoxygenase transgenic mice, LC-MS-MS identified RvD1, PD1 and 17-HDHA with reduced PGE 2 from activated macrophages 75 . LXA 4 , PD1 and RvD1 each reduced cytokines (for example, MCP-1) from endothelial cells and adhesion molecules (P-selectin and VCAM-1) but not ICAM-1. LXA 4 , PD1 and RvD1 also enhanced uptake of apoptotic thymocytes, which could contribute to the anti-atherogenic role of this pathway in mice. This process can also be manipulated by diet to govern severity of atherogenic lesions 75, 76 . RvE1 is protective in periodontal disease but, unlike LXA 4 , exogenous RvE1 also stimulates bone regeneration in rabbit models of periodontitis 60, 77 . In murine models of arthritis, RvD1 and 17-HDHA reduce pain and tissue damage, proving more potent than either steroid or pain treatments 78 . Unresolved inflammation, epithelial and microvascular injury can lead to excessive fibrosis (Fig. 1) that impairs organ function. Leukotrienes are profibrotic, and in people with scleroderma interstitial lung disease, LXA 4 is present in the lungs at levels that seem unable to counter-regulate profibrotic factors 79 . In animals, an exogenous aspirin-triggered lipoxin analogue reduces pulmonary fibrosis induced by the antibiotic bleomycin 80 , and both LXA 4 and benzo-LXA 4 reduce renal fibrosis 81 . Exogenous RvE1 and RvD1 protect from renal fibrosis, reducing collagen I and IV, α-SMA and fibronectin 82 . In addition, exogenous RvD1 reduces pro-inflammatory mediators that are generated in response to cigarette smoke and pulmonary toxicants 83 .
Organ regeneration and wound healing
In mice, exogenous SPMs have been found to stimulate would healing in a range of studies. LXA 4 stimulates re-epithelialization of the cornea in a gender-specific fashion in mice 84 ; when applied to wounds, RvE1, RvD1 and RvD2 each stimulate murine dermal healing, reducing neutrophilic infiltration and stimulating re-epithelialization 85 ; RvD1 and RvD2 also stimulate wound healing in diabetic mice 21, 86 . Macrophages have a role in wound healing and organ regeneration, and the macrophage-derived maresin pathway stimulates tissue regeneration. This pathway (Fig. 2) is present in the flatworm Dugesia tigrina, in which RvE1 and MaR1 were each found to reduce regeneration times (speed of head-segment regrowth) 23 . Given the importance of tissue regeneration in trauma and infection, regulation of resolution programs could hold promise as a therapy.
SPMs in adaptive immunity
Lymphoid tissue such as mouse spleen produces RvD1, 17-HDHA, PD1 (ref. 87 ) and LXA 4 (ref. 88) from endogenous sources, which was identified using mass spectrometry, suggesting these products are strategically positioned to act on lymphocytes (Fig. 1) . Both exogenous 17-HDHA and RvD1 increase human B-cell immunoglobulin-M and immunoglobulin-γ, a response that was not shared by PD1. B-cell differentiation is enhanced by exogenous 17-HDHA towards the CD27 + CD38 + antibody-secreting cell phenotype 87 . PD1 is biosynthesized by human T-helper-2-skewed mononuclear cells by a 16(17)-epoxy-protectin intermediate (Fig. 2) and reduces T-cell migration, TNF-α and interferon-γ, promoting T-cell apoptosis 89 . Exogenous LXA 4 , RvE1 and PD1 each upregulate expression of the chemokine receptor CCR5 on leukocytes, facilitating their clearance and resolution 90 . Exogenous PD1 reduces CD4 + T-cell infiltration into cornea 66 , as does RvE1 (ref. 67) , in herpes simplex viral infections. Exogenous RvD1 reduces CD11b + leukocytes and CD4 + and CD8 + T lymphocytes in uveitis 91 . Exogenous RvE1 and RvD1 each regulate T-cell activation in choroid and retina, and are biosynthesized in this tissue, as identified by LC-MS-MS 92 . Exogenous RvE1 induces apoptosis of activated T cells by the induction of 2,3-dioxygenase in dendritic cells, representing a new functional subtype of dendritic cells that have a role in resolution 93 . Exogenous RvE1 has also been shown to reduce numbers of mouse CD4 + T cells and CD8 + T cells in atopic dermatitis 94 .
Neuroinflammation and pain
Mouse and human brains have the capacity to produce resolvins and protectins, as do human microglial cells, in which they reduce cytokine expression 8, 95, 96 . And the production of SPMs by the brain cells of trout 
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indicates that they are conserved from fish to humans 88 . In ischaemic mouse brains, immunoreactive resolvins, protectins and their aspirintriggered forms are produced 97 ; in these mice synthetic SPMs are protective, downregulating excess leukocyte infiltration and reducing local neuronal injury, COX-2 induction, and levels of IL-1β and NF-κB. Thus, in the brain, DHA could be a precursor to neuroprotective signalling pathways evoked by ischaemia reflow tissue injury. The DHA product 10,17-dihydroxy-protectin is called neuroprotectin D1 (NPD1) when biosynthesized and acting in neural tissues and retinal epithelial cells owing to its potent actions to reduce neuroinflammation and protect neural cells 98 . DHA is enriched in the brain, synapses and the retina, in which it is known to have a protective role, but its role as a precursor to mediators in resolution and neuroprotection is still emerging. Synthetic NPD1 has a potent protective role in the nervous system, reducing stress pathways that lead to cell death and increase cell survival, and in several ocular models of important diseases (such as herpes 66 and neovascularization in the eye 99 ) NPD1 targets microglia 8, 98, 99 . Human neutrophils biosynthesize 17R-NPD1/PD1 that is enhanced by aspirin in vitro, limiting neutrophil transmigration and enhancing macrophage efferocytosis 37 . Synthetic aspirin-triggered NPD1 reduces brain oedema in penumbra and subcortical lesion size, and improves neurological scores 100 .
In the brains of people with Alzheimer's disease, NPD1 is reduced 96 and the resolution pathway (SPM receptors and products) is diminished 101 . LXA 4 and RvD1 are reduced in cerebrospinal fluid and hippocampus, which correlated with lower scores on the mini-mental state examinations in these patients. These findings provide further evidence that failed resolution of the inflammatory response could contribute to human disease 101 . RvD1 added to macrophages from patients with Alzheimer's in vitro reduces the macrophages' pro-inflammatory phenotype and enhances phagocytosis of amyloid-β 102 . This is consistent with the suggestion that resolvins promote clearance of amyloid-β deposition to reduce inflammation in Alzheimer's. Hence, SPMs might have homeostatic roles in brain and peripheral tissues, whereby each SPM has selective functions to reduce neuroinflammation.
Inflammation can evoke persistent pain. ALX/FPR2 is expressed on spinal astrocytes, and local spinal delivery of synthetic LXA 4 , LXB 4 or their metabolically stable analogues reduces inflammation-induced pain 103 . Many SPMs dampen pain; in mice, they have specific targets of action 104 , as demonstrated with RvE1 and RvD1 for inflammatory pain involving both central and peripheral sites 105 . RvE1 administered intrathecally in mice is more potently analgesic than morphine or a COX-2 inhibitor. The RvE1 receptor ChemR23 is present in dorsal root ganglia, in which synthetic RvE1 regulates phosphorylation of ERKdependent transient receptor potential vanilloid subtype-1 (TRPV1) inhibition and TNF-α-mediated hyperalgesia, centrally. In postsynaptic neurons, synthetic RvE1 inhibits glutamate and TNF-α stimulation of N-methyl-d-aspartic acid (NMDA) receptor and mechanical allodynia 105 . Synthetic RvD1, RvD2 and PD1/NPD1 each reduce pain by the inhibition of specific TRPV channels 106, 107 . MaR1 inhibits TRPV1 in neurons and blocks capsaicin-induced inward current (the half-maximum inhibitory concentration is 0.49 nM), diminishing inflammatory and chemotherapy-evoked neuropathic pain in mice 24 . Both aspirin-triggered RvD1 and 17R-HDHA reduce adjuvant-induced arthritis in rats and associated pain 78 , reduce NF-κB and COX-2 expression in the spinal cord, and, in arthritic joints, reduce TNF-α and IL-1β levels. In addition to leukocytes and microglia, SPM receptors are present on neuronal bodies, nerve terminals (skin and muscle) and synaptic terminals, on which they regulate specific transient receptor potential channels. For example, RvE1-ChemR23 interaction in dorsal root ganglion regulates TRPV1, but not by direct activation of channels like endocannabinoids 104 or other lipids that directly bind transient receptor potential channels; instead, each SPM activates a specific GPCR in the pico-nanomolar range to regulate channels involved in pain signalling.
Direct comparisons between synthetic LXA 4 and aspirin-triggered RvD1 mechanical hypersensitivity in a rat model of inflammationinduced pain indicate that both effectively reduce hypersensitivity and pro-inflammatory mediators from astrocytes 108 . Local increases in pro-inflammatory mediators can result in cognitive decline, which can occur after major surgery or critical illness and is a major public health concern. Systemic aspirin-triggered RvD1 prophylaxis helps to prevent memory decline in mice that have undergone surgery, protecting them from post-operative neuronal dysfunction 109 . Whether SPM actions in mouse pain models translate to reducing human pain and improving cognition remains of interest.
Towards human translation
Because resolvins and protectins were identified in mouse exudates, it was essential to establish their biosynthesis by human leukocytes and in human tissues 7, 8, 95 (Box 2). Using mass spectrometry, RvE1 and RvE2 can be identified in human blood 47, 61, 110 , provided EPA or DHA is available. RvD1 and RvD2 are found in human plasma and serum 111 . The capacity of murine placenta to form resolvins (RvD1 and RvD2) and protectins (PD1 and 10S,17S-diHDHA 112 , also known as PDx) was confirmed by mass spectrometry, and the levels of each were increased by dietary omega-3 (ref. 113) . Strategically, SPMs are also present in human breast milk 114 : LXA 4 , RvD1 and RvE1 were identified in milk of mothers in their first month of lactation using mass spectrometry 114 . These identifications, made possible with LC-MS-MS and the availability of SPMs, could provide opportunities for the rigorous assessment of SPM functional roles in human physiology and their potential for therapy.
Evidence for lipid-mediator class switching in humans has recently been reported 115 . LC-MS-MS lipidomic analysis of venous blood collected after strenuous resistance exercise identified lipid mediators in peripheral blood. Prostanoids in the initial post-exercise recovery phase were temporally followed by leukotrienes and p450-derived eicosanoids (EETs), as well as lipoxins, resolvins and protectins. The NSAID ibuprofen, which is widely used for muscle aches and pains, blocked exercise-induced prostanoids, reduced LTB 4 , and both delayed and diminished the SPM response, as identified by mass spectrometry. This study of resistance exercise in humans illustrates the acute response of pro-inflammatory mediators, presumably from muscle, and the mediators' potential link to resolution programs 115 . However, the amount of resolvins and protectins reported are relative, and additional studies are needed to establish their levels in healthy exercising individuals.
In a 60-patient double-blind trial 116 of infants with eczema, topical 15(R/S)-methyl-LXA 4 relieved severity and improved quality of life without apparent adverse events. In these infants, the lipoxin analogue was as effective as a topical steroid.
Looking forward
For autacoids, it is when and where that counts, and it is important to emphasize that the first response in acute inflammation is ubiquitous and mounts throughout the body. SPMs are agonists of resolution. Each stimulates cessation of neutrophil influx, efferocytosis and enhances phagocytosis for microbial containment -signs of resolution (Fig. 1) . These steps are the defining SPM functions. Each SPM pathway has additional, non-redundant functions on target cell types. At the cellular and molecular levels, SPMs counter-regulate pro-inflammatory mediators (eicosanoids, chemokines, cytokines 33 and adipokines 22 ); regulate specific miRNAs 53 and cell traffic; and enhance microbial killing by receptor-mediated mechanisms in animal models in vivo and with human neutrophils and macrophages 10, 13, 21 .
Results from preclinical disease models 10 suggest that treatment of inflammation-associated disease might be possible with SPM agonists that stimulate resolution and protect organs from collateral damage (Box 2). RvE1, MaR1 and NPD1/PD1 are each in clinical development programs. An RvE1 mimetic is in clinical trials for ocular indications (http://www.auventx.com/auven/products/rx10045.php), and NPD1/ PD1 is in clinical development for neurodegenerative diseases (http:// www.anidapharma.com/lead-molecule.html); given their ability to 
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regulate inflammation resolution without immunosuppression, it is hopeful they will become therapies.
Because identifying SPMs in human tissues relies on LC-MS-MSbased approaches and internal standards that have only recently become available, at this point relatively few studies have demonstrated the presence of SPMs in human tissues (such as blood, milk, and adipose and brain tissue). Hence, evidence for SPM formation in humans is at a very early stage, and their functional importance in human health and diseases remains to be established. Whether SPMs have physiological actions in target tissues in humans, now that we know that they are produced in levels that show potent selective actions in animals 10, 19 , can now be addressed (Box 2) -along with the impact of anti-inflammatories on SPM pathways -using LC-MS-MS-based lipid-mediator-SPM profiling of human tissues. The SPMs produced by human apoptotic neutrophils and macrophages can be identified using LC-MS-MS profiling 13 without omega-3 EFA supplementation; it is therefore now possible, with the sensitivity of LC-MS-MS, to determine individual human SPM profiles (personalized lipid mediator-SPM metabolomics). This personalized metabolomics can be used to determine the relationship to resolution mechanisms. It is also important to determine, in healthy individuals, the omega-3 EFA supplementation and doses that might increase or diminish SPMs within specific tissues. Importantly, it is crucial to assess whether human diseases that are characterized by excessive inflammation result from failed resolution mechanisms because of the absence of specific SPM pathways and whether these mechanisms can be rescued either by EPA or DHA, or by therapeutic versions of SPM mimetics. Given that resolution of inflammation is a fundamental process in all organs, new approaches for stimulating resolution and using SPMs as pathway markers could soon be possible, as could determining the relationship of SPMs to nutrition in humans.
SPMs have emerged from animal models as potential regulators in physiological pathways of resolution and unresolved inflammation that can affect infection, pain, obesity, organ protection 21 and inflammatory diseases (Box 2) beyond the roles of their omega-3 EFA precursors in intermediary metabolism and membrane dynamics. Identification of SPM bioactive metabolomes and an appreciation that exudates can drive resolution, partly through SPMs, sets a new terrain to evaluate resolution physiology and pharmacology, in which SPMs are crucial as chemical signals for catabasis and host defence. Note added in proof: A paper recently appeared online while the current Review was in press reporting the quantification of pro-resolving mediators using a new approach in human tissues and their functional relationship to known eicosanoids 121 . ■
